A new study has linked a type of injectable birth control with meningioma. The manufacturer says the claims are “without ...

A well-known injectable birth control method is under fire after multiple studies linked it to a specific kind of brain tumor, and now, lawsuits are piling up against the drugmaker. […] The post ...

A new study allegedly discovered that women using a specific form of birth control had a "significantly higher risk" of ...

The hormonal treatments cyproterone acetate and medroxyprogesterone acetate are the most effective at reducing hot flushes, a common side-effect in men being treated with hormone therapy for ...

On Thursday in Washington, D.C., the U.S. Food and Drug Administration (FDA) convened a panel of top experts to reassess the ...

Use of the injectable contraceptive depot medroxyprogesterone acetate, common in areas such as sub-Saharan Africa with high HIV-1 prevalence, is associated with suppression of the immune response ...

Men with prostate cancer who reported having significant hot flushes during androgen suppression treatment had a better hormonal response with cyproterone and medroxyprogesterone compared with ...

Sixty patients were entered (thalidomide:medroxyprogesterone = 29:31; median age, 59 [thalidomide], 60 [medroxyprogesterone]; No. of patients assessable for response, 22 [thalidomide], 26 ...

Medroxyprogesterone acetate has been used to treat breast and renal cell cancers. The doses used in these settings (up to a 1000 mg/day) achieve plasma levels up to 15 μ M.

Compared with the medroxyprogesterone acetate group, the levonorgestrel-releasing intrauterine system group had a significantly greater reduction in median menstrual blood loss at study end (-128. ...